康缘药业：车前子片获临床试验批准通知书

Core Viewpoint - Kangyuan Pharmaceutical has received the Clinical Trial Approval Notice for Cheqianzi Tablets from the National Medical Products Administration, indicating progress in its drug development pipeline for treating diabetic kidney disease [1] Group 1: Company Developments - The approval pertains to Cheqianzi Tablets, which are indicated for promoting diuresis, clearing heat, and transforming dampness, specifically for the treatment of diabetic kidney disease with damp-heat syndrome [1]